Abstract: For in mold spraying, a double-inclined mixing nozzle is connected obliquely and fixedly with a side surface of a third half-mold through a lateral sealing structure and connected with a side surface of a first half-mold in an inclined and sealing manner, side faces of a first half-mold and the third half-mold are respectively provided with installation inclined surfaces. A lateral sealing structure includes a mounting plate and a sealing member. The sealing member is sleeved on the double-inclined mixing nozzle and is in transition fit with the double-inclined mixing nozzle and the mounting plate respectively. A butt sealing groove provided on the installation inclined surface of the first half-mold and is in sealing fit with the mounting plate.

Abstract: The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present disclosure further relates to methods of inhibiting viral replication including contacting one or more cells that have been infected with a virus with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the virus comprises a flavivirus. Also disclosed is a method of treating and/or preventing a flavivirus infection and/or a condition resulting from a flavivirus infection including administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof under conditions effective to treat and/or prevent a flavivirus infection and/or a condition resulting from a flavivirus infection.

Abstract: The present disclosure relates to a Prp8 intein splicing inhibitor. The present disclosure further relates to a method of treating and/or preventing a fungal infection, said method comprising administering a Prp8 intein splicing inhibitor under conditions effective to treat and/or prevent a fungal infection. Also disclosed is a method of inhibiting Prp8 intein expression or activity in a cell or tissue, said method comprising administering a compound under conditions effective to inhibit Prp8 intein expression or activity in a cell or tissue. Further disclosed are methods for screening for compounds that inhibit Prp8 intein splicing comprising an assay and a kit for predicting the likelihood of Prp8 inhibition.

Abstract: The current invention provides a method of activating fibroblast and myofibroblast apoptosis in a tissue of a mammal, comprising administering to the tissue a therapeutically effective amount of a composition comprising an siRNA molecule that binds to an mRNA that codes for TGFB1 protein in a mammalian cell, an siRNA molecule that binds to an mRNA that codes for COX-2 protein in a mammalian cell, and a pharmaceutically acceptable carrier comprising a pharmaceutically acceptable histidine-lysine polymer. The invention also provides additional methods for using this composition.

Abstract: The invention relates generally to novel EPAC1 activators, such as Formula I and II and the preparation thereof as well as the use of EPAC1 activators disclosed herein as to selectively activate EPAC1 in cells.

Abstract: Certain embodiments describe antiviral compounds and related methods of using such compounds.

Abstract: The present invention relates to a method of inhibiting or control wax formation during stimulation treatment of a well. More specifically, the present invention proposes the use of aqueous polymer dispersions suitable as wax inhibitor compositions which are compatible with aqueous fracturing fluids.

Abstract: According to a high-intensity focused ultrasonic apparatus and a control method, an image of a region to be treated is obtained by means of an imaging device, a working assembly and a target coordinate point in the region to be treated are located by means of an optical tracking device, so that a positioning device can clamp the working assembly to quickly and accurately move to a working position corresponding to the target coordinate point, thereby enabling the working assembly to quickly and accurately release a high-intensity focused ultrasonic pulse to the target coordinate point, which improves not only the treatment accuracy but also the treatment efficiency of the high-intensity focused ultrasonic apparatus.

Abstract: A series of substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3'-indoline]-2',5(3H)-dione analogues, the use thereof and the preparation thereof.

Abstract: A series of substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3?-indoline]-2?,5(3H)-dione analogues, the use thereof and the preparation thereof.

Abstract: Certain embodiments are directed to methods of using BRD4 inhibitors for treating IgE-mediated diseases.

Abstract: The present invention relates to novel small molecules Formula I and pharmaceutically acceptable salts thereof as well as the preparation and the use thereof to inhibit FGF13-1b.

Abstract: The invention relates generally to the following novel fendiline derivatives, and the preparation and use thereof: Formula I (I) and Formula II (II)

Abstract: A method for building a simulation program with integrated circuit emphasis (SPICE) circuit model of an optical coupler is provided. The method includes: providing a plurality of electrical parameters of the SPICE circuit model of the optical coupler circuit for a plurality of temperature values, and building the SPICE circuit model of the optical coupler at each of the temperature values according to the electrical parameters of the optical coupler for each of the temperature values, so as to form a plurality of temperature-independent SPICE circuit models of the optical coupler; forming a plurality of temperature-voltage conversion switch circuit elements by utilizing control of a voltage source and temperature characteristics of an impedance; and connecting the temperature-voltage conversion switch circuit elements to the temperature-independent SPICE circuit models of the optical coupler, respectively, so as to build a temperature characterized SPICE circuit model of the optical coupler.

Abstract: Embodiments are directed to novel GPR52 activators. In particular, a series of novel 1-(pyrimidin-4-yl)indoline-4-carboxamide analogs that have been identified as potent and selective GPR52 agonists. The optimized GPR52 agonist that, for example, can be used as a valuable pharmacological tool or a drug candidate for investigating the physiological and therapeutic potential of GPR52 activation for various human diseases.

Abstract: The present invention relates to a method of inhibiting or control wax formation during stimulation treatment of a well. More specifically, the present invention proposes the use of aqueous polymer dispersions suitable as wax inhibitor compositions which are compatible with aqueous fracturing fluids.

Abstract: The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present disclosure further relates to methods of inhibiting viral replication including contacting one or more cells that have been infected with a virus with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the virus comprises a flavivirus. Also disclosed is a method of treating and/or preventing a flavivirus infection and/or a condition resulting from a flavivirus infection including administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof under conditions effective to treat and/or prevent a flavivirus infection and/or a condition resulting from a flavivirus infection.

Abstract: The present application provides, in some aspects, methods of treating cancers, such as homologous recombination (HR)-deficient cancers. In some embodiments, the disclosure provides a method for treating cancer by administering to a subject a compound of Formula (I):(I), or a pharmaceutically acceptable salt thereof.